GHENT, BELGIUM--(Marketwire - January 10, 2012) -
GHENT, Belgium, 10 January 2012 - Ablynx [Euronext Brussels: ABLX]
announced that it has been granted an extended Certificate of Good
Practice (GMP) from the Federal Agency for Medicines and Health Products
in Belgium for its new GMP unit at its headquarters in Ghent, after having
inspected in November 2011.
Having received this accreditation, Ablynx's GMP unit will now perform
testing on Drug Substance and Drug Product batches and independently
stability studies on these batches. The large scale GMP
Nanobodies® will continue to be outsourced to contract
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "GMP certification
laboratories in Ghent is a testament to Ablynx's commitment to
perform at a high standard in our internal and partnered development
This is an important step forward as we continue to transform into a
About Good Manufacturing Practice
Good Manufacturing Practice (GMP) is that part of a Quality Management
which ensures that products are consistently produced and controlled
quality standards appropriate to their intended use.
About the Federal Agency for Medicines and Health Products
The Federal Agency for Medicines and Health Products (FAMHP) is the
authority responsible for the quality, safety and efficacy of
health products in Belgium.
Ablynx is a biopharmaceutical company engaged in the discovery and
of Nanobodies(®), a novel class of therapeutic proteins based on
antibody fragments, for a range of serious and life-threatening human
including inflammation, haematology, oncology and pulmonary disease.
Company has over 25 programmes in the pipeline and seven Nanobodies in
development. Ablynx has ongoing research collaborations and
partnerships with major pharmaceutical companies, including
Ingelheim, Merck Serono, Novartis, and has had a collaboration with
Company is headquartered in Ghent, Belgium and currently employs over
people. More information can be found on www.ablynx.com.
Complete version of the press release:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE